Correction: High-normal levels of hs-CRP predict the development of non-Alcoholic fatty liver in healthy men (PLoS ONE (2017) 12:2 (e0172666) DOI: 10.1371/journal.pone.0172666);High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men

PLoS ONE

Volumn 12, Issue 2, 2017, Pages

  Lee, Jieun ^a   Yoon, Kijung ^b   Ryu, Seungho ^b   Chang, Yoosoo ^b   Kim, Hyoung Ryoul ^c  

^a Ajou University Medical Center   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ABDOMINAL RADIOGRAPHY; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; DIAGNOSTIC IMAGING; DRINKING BEHAVIOR; ECHOGRAPHY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; ALCOHOL DRINKING; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; EXERCISE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SMOKING; SURVEYS AND QUESTIONNAIRES; TRIGLYCERIDES; ULTRASONOGRAPHY;

EID: 85013980260     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0206834     Document Type: Erratum

References (41)

1. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231. doi: 10.1056/ NEJMra011775 PMID: 11961152
2. Musso G, Gambino R, Cassader M, Pagano G (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617-649. doi: 10.3109/07853890.2010.518623 PMID: 21039302
3. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. (2007) Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47: 239-244. doi: 10.1016/j.jhep.2007.02.007 PMID: 17400323
4. Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47 Suppl: S2-6.
5. Wong VW (2013) Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 28: 18-23.
6. Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152. doi: 10.1172/JCI22422 PMID: 15254578
7. Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 98: 960-967. doi: 10.1111/j.1572-0241.2003.07486.x PMID: 12809815
8. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28: 339-350. doi: 10.1055/s-0028-1091978 PMID: 18956290
9. Musso G, Cassader M, Gambino R (2012) Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. Hepatology 56: 788-789. doi: 10.1002/hep.25677 PMID: 22371327
10. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, et al. (2011) High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 60: 829-836. doi: 10.1136/gut.2011. 237974 PMID: 21339204
11. Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, et al. (2013) Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 19: 6453-6457. doi: 10.3748/wjg.v19.i38.6453 PMID: 24151364
12. Rodriguez-Hernandez H, Simental-Mendia LE, Rodriguez-Ramirez G, Reyes-Romero MA (2013) Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013: 678159. doi: 10.1155/2013/678159 PMID: 23690772
13. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349: 462-466. PMID: 9040576
14. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middleaged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242. PMID: 9892589
15. Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537-547. PMID: 8797513
16. Libby P, Okamoto Y, Rocha VZ, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74: 213-220. PMID: 20065609
17. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC (1996) C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312: 1061-1065. PMID: 8616412
18. Ridker PM, Buring JE, Cook NR, Rifai N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397. PMID: 12551861
19. Chiang CH, Huang CC, Chan WL, Chen JW, Leu HB (2010) The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clin Biochem 43: 1399-1404. doi: 10.1016/j. clinbiochem.2010.09.003 PMID: 20846522
20. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, et al. (2013) Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol 12: 548-555. PMID: 23813132
21. Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, et al. (2012) Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther 14: 152-158. doi: 10.1089/dia.2011.0213 PMID: 22149546
22. Ndumele CE, Nasir K, Conceicao RD, Carvalho JA, Blumenthal RS, Santos RD. (2011) Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 31: 1927-1932. doi: 10.1161/ATVBAHA.111. 228262 PMID: 21546603
23. Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. (2013) Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS One 8: e49286. doi: 10.1371/journal.pone.0049286 PMID: 23326306
24. Chang Y, Ryu S, Sung E, Jang Y (2007) Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem 53: 686-692. doi: 10.1373/ clinchem.2006.081257 PMID: 17272484
25. Chang Y, Ryu S, Sung E, Woo HY, Cho SI, Yoo SH, et al. (2009) Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut 58: 1419-1425. doi: 10.1136/gut.2008.161885 PMID: 19505882
26. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS (2007) gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 53: 71-77. doi: 10.1373/ clinchem.2006.078980 PMID: 17110470
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. PMID: 3899825
28. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S (2003) Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 38: 954-961. doi: 10.1007/s00535-003-1178-8 PMID: 14614602
29. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722-728. PMID: 16287793
30. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497. PMID: 11368702
31. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0. CO;2-S PMID: 9686693
32. Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. (2009) Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr 12: 497-506. doi: 10.1017/S1368980008002802 PMID: 18547457
33. Festa A, D'Agostino R Jr., Howard G, Mykkanen L, Tracy RP, Haffner SM. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102: 42-47. PMID: 10880413
34. Kawada T, Hasegawa M (2012) Predictive ability of serum high-molecular-weight adiponectin in combination with serum insulin and serum C-reactive protein for the presence of metabolic syndrome. Ann Hum Biol 39: 108-112. doi: 10.3109/03014460.2011.652170 PMID: 22324836
35. Lambert M, Delvin EE, Paradis G, O'Loughlin J, Hanley JA, Levy E. (2004) C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem 50: 1762-1768. doi: 10.1373/clinchem.2004.036418 PMID: 15308596
36. Bozic MA, Subbarao G, Molleston JP (2013) Pediatric nonalcoholic fatty liver disease. Nutr Clin Pract 28: 448-458. doi: 10.1177/0884533613489153 PMID: 23917437
37. Tarantino G, Finelli C (2013) Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 19: 6735-6743. doi: 10.3748/wjg.v19.i40.6735 PMID: 24187449
38. Feingold KR, Grunfeld C (1992) Role of cytokines in inducing hyperlipidemia. Diabetes 41 Suppl 2: 97-101.
39. Kim JH, Baik HW, Yoon YS, Joung HJ, Park JS, Park SJ, et al. (2014) Measurement of antioxidant capacity using the biological antioxidant potential test and its role as a predictive marker of metabolic syndrome. Korean J Intern Med 29: 31-39. doi: 10.3904/kjim.2014.29.1.31 PMID: 24574831
40. Kumar R, Prakash S, Chhabra S, Singla V, Madan K, Gupta SD, et al. (2012) Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res 136: 229-236. PMID: 22960889
41. Yatsuzuka S, Shimomura Y, Akuzawa M, Ando Y, Kobayashi I, Nakano T, et al. (2014) Plasma adiponectin is a more specific marker of fatty liver than a marker of metabolic syndrome in Japanese men. Ann Clin Biochem 51: 68-79. doi: 10.1177/0004563213487892 PMID: 23897104